Fear of recurrence and its impact on quality of life in patients with hematological cancers in the course of allogeneic hematopoietic SCT

S. Sarkar, A. Scherwath, L. Schirmer, F. Schulz-Kindermann, K. Neumann, M. Kruse, A. Dinkel, S. Kunze, F. Balck, N. Kröger, U. Koch, A. Mehnert

Publikation: Beitrag in FachzeitschriftArtikelBegutachtung

69 Zitate (Scopus)

Abstract

We examined the course and the prevalence of a high fear of cancer recurrence (FCR) in patients undergoing allogeneic PBSC transplantation (hematopoietic SCT (HSCT)) before HSCT (N=239), 100 days after (n=150, and 12 months after allogeneic HSCT (n=102). The Fear of Progression Questionnaire-Short Form (FoP-Q-SF), the EORTC Quality of Life Questionnaire, and the Hospital Anxiety and Depression Scale were used. Pre-HSCT 36% of patients, 100 days after HSCT 24% of patients, and 1 year after HSCT 23% of patients fulfilled the criteria for high FCR (FoP-Q-SF cutoff=34). Being married (b=2.76, P=0.026), female gender (b=4.45, P<0.001) and depression (b=4.44, P<0.001) were significantly associated with FCR at baseline. One hundred days after HSCT, depression significantly predicted FCR (b=6.46, P<0.001). One year following HSCT, female gender (b=6.61, P=0.008) and higher depression were (b=4.88, P=0.004) significant predictors for FCR. Over the three assessment points, patients with high FCR had a significantly lower quality of life compared to patients with low FCR in physical functioning (P=0.019), role functioning (P=0.003), emotional functioning (P<0.001), cognitive functioning (P=0.003), social functioning (P<0.001) and global quality of life (P<0.001). Our data provide evidence that FCR is a prevalent problem in patients with hematological malignancies and has a significant adverse impact on health-related quality of life.

OriginalspracheEnglisch
Seiten (von - bis)1217-1222
Seitenumfang6
FachzeitschriftBone Marrow Transplantation
Jahrgang49
Ausgabenummer9
DOIs
PublikationsstatusVeröffentlicht - 2 Sept. 2014
Extern publiziertJa

Fingerprint

Untersuchen Sie die Forschungsthemen von „Fear of recurrence and its impact on quality of life in patients with hematological cancers in the course of allogeneic hematopoietic SCT“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren